Expects to end 2025 at ~2.8x. Says entering “exciting period” for biosimilar portfolio. Says has made “significant progress” with transformation program. Says set to deliver on 2027 targets. Comments taken from Q3 earnings conference call.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA: